Drug-Induced Cardiac Abnormalities in Premature Infants and Neonates

Luana Pesco Koplowitz, MD, PhD
DUCK FLATS Pharma, LLC
Elbridge, NY
Barry Mangum, PharmD
Duke University, Raleigh, NC
Specialty Pediatric Populations
Objective

• Assessment of medications that can cause cardiac abnormalities in premature infants and neonates
• Differences in the physiology of premature infants and neonates that make them more susceptible to drug-induced cardiac events
• Pharmacological mechanisms of action of common cardiac toxicities
Objectives

• Pharmacological animal models of cardiovascular drug effects in premature infants and neonates
• Common congenital conditions which can exacerbate drug-induced cardiac adverse events
• Assessments of alternate treatments which can minimize cardiac adverse events.